Polyglutamic acid-vitamin E amphiphilic conjugate as well as preparation method and application thereof
By forming the polyglutamate-vitamin E amphiphilic conjugate formed by the esterification reaction of vitamin E and polyglutamic acid, the problem of failure of TPGS in the prior art has been solved, and the problem of failure of TPGS to retain antioxidant properties and biological toxicity in the prior art has been achieved. Widely used in a variety of emulsification systems and excellent antioxidant properties to meet diverse needs.
Patent Information
- Application Number
- CN202411545966.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-01
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, although the hydrophilic modified materials of vitamin E such as TPGS have good amphiphilicity, they fail to retain their original antioxidant properties, and the immobility of PEG molecular weight and the uniqueness of the graft site limit the Its application in emulsification systems, coupled with the potential biotoxicity problems, is difficult to meet the needs of diversified emulsification systems.
Using polyglutamic acid-vitamin E amphiphilic conjugates, by combining vitamin E with polyglutamic acid through esterification, a material with excellent antioxidant and amphiphilic properties is formed, and by regulating polyglutamic acid The ratio to vitamin E is to meet the needs of different emulsification systems.
It has achieved wider application in a variety of emulsification systems, significantly improved antioxidant performance, and has broad application potential in crop production, health products, medicinal auxiliary materials, feed additives, cosmetics and functional foods.
Smart Images

Figure CN119081105A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioactive polymer materials, and in particular to a polyglutamic acid-vitamin E amphiphilic conjugate and a preparation method and application thereof. Background Art
[0002] Vitamin E (VE) is a highly lipophilic compound, and its extremely low water solubility greatly limits its application in many fields. Therefore, hydrophilic modification of VE to enhance its solubility and application range has become an important exploration direction. Vitamin E polyethylene glycol succinate (TPGS) is a water-soluble derivative of VE (i.e. VE modified by polyethylene glycol (PEG)). It is formed by the reaction of the carboxyl group of VE and the hydroxyl group of PEG. By introducing PEG, it successfully combines the lipophilic properties of VE and the hydrophilic long chain advantages of PEG, showing good amphiphilicity and water solubility. However, although the PEG block imparts water solubility, it fails to retain the original antioxidant properties of VE. The fixed molecular weight of PEG and the uniqueness of the grafting site limit the application of TPGS in emulsification systems. In addition, its potential biological toxicity issues have prompted us to seek more ideal hydrophilic modified materials.
[0003] Polyglutamic acid, as a biomaterial certified by the State Food and Drug Administration, has good biocompatibility and biodegradability due to its peptide bond structure identical to that of natural proteins. In addition, the carboxyl group of the polyglutamic acid side chain gives it excellent water solubility and chemical modification potential, making it an ideal hydrophilic biopolymer material. Currently, the prior art discloses a technical solution for preparing drug-loaded nanomicelles by grafting VE with polyethylene glycol-polyglutamic acid block copolymers, but the polyglutamic acid used in the prior art has a single configuration and is difficult to meet the needs of a diversified emulsification system, and lacks additional functional expansions such as antioxidant properties. Summary of the invention
[0004] The purpose of the present invention is to provide a polyglutamic acid-vitamin E amphiphilic conjugate and a preparation method and application thereof. The polyglutamic acid-vitamin E amphiphilic conjugate exhibits wider practicability in a variety of emulsified systems and exhibits more excellent antioxidant properties.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions: The present invention provides a polyglutamic acid-vitamin E amphiphilic conjugate having a structure shown in Formula 1 or Formula 2: Formula 1, Formula 2; In Formula 1 and Formula 2, m+n=15~2300, and n is any natural number between 1 and 100.
[0006] Preferably, the grafting rate of vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate is 0.1-25%.
[0007] The present invention also provides a method for preparing the polyglutamic acid-vitamin E amphiphilic conjugate described in the above technical solution, comprising the following steps: The polyglutamic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, p-dimethylaminopyridine and the first solvent are first mixed and then subjected to a condensation reaction to obtain an activation solution; The vitamin E solution and the activation solution are mixed for a second time, and an esterification reaction is performed to obtain the vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate.
[0008] Preferably, the polyglutamic acid is γ-polyglutamic acid or α-polyglutamic acid; The number average molecular weight of the γ-polyglutamic acid is 2000-300000Da; the number average molecular weight of the α-polyglutamic acid is 2000-10000Da.
[0009] Preferably, the concentration of polyglutamic acid in the mixed solution obtained by the first mixing is 0.05-7.5 mmol / L, and the concentration of carboxyl groups in the polyglutamic acid in the mixed solution obtained by the first mixing is 112-115 mmol / L; The molar ratio of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to polyglutamic acid is (0.3-1.2):1; The molar ratio of the p-dimethylaminopyridine to the carboxyl group in polyglutamic acid is (0.3-1):1.
[0010] Preferably, the condensation reaction is carried out at room temperature for 1 to 4 hours.
[0011] Preferably, the concentration of vitamin E in the vitamin E solution is 50-500 mmol / L; The vitamin E in the vitamin E solution is D-α-vitamin E; The molar ratio of the hydroxyl group in the vitamin E in the vitamin E solution to the carboxyl group in the polyglutamic acid in the mixed solution obtained by the first mixing is (0.5-2):1.
[0012] Preferably, the esterification reaction is carried out at a temperature of 25-30° C. and for a time of 24-48 hours.
[0013] Preferably, after the esterification reaction is completed, the method further comprises the following steps: first precipitation, first centrifugation, first redissolution, second precipitation, second centrifugation, first drying, second redissolution, dialysis, third centrifugation and second drying.
[0014] The present invention also provides the use of the polyglutamic acid-vitamin E amphiphilic conjugate described in the above technical solution or the polyglutamic acid-vitamin E amphiphilic conjugate prepared by the preparation method described in the above technical solution in the field of anti-oxidation or the field of drug-loaded nano micelles.
[0015] The present invention provides a polyglutamic acid-vitamin E amphiphilic conjugate having a structure shown in Formula 1 or Formula 2: Formula 1, Formula 2; In Formula 1 and Formula 2, m+n=15~2300, and n is any natural number between 1 and 100.
[0016] Compared with the prior art, the polyglutamic acid-vitamin E amphiphilic conjugate of the present invention has the following beneficial effects: The polyglutamic acid-vitamin E amphiphilic conjugate of the present invention uses polyglutamic acid as the main chain, which itself has good hydrophilicity, and the product after decomposition is glutamic acid that can be absorbed and metabolized by the human body and has no biological toxicity; The present invention selects vitamin E as the side chain, which not only ensures the excellent biocompatibility of polyglutamic acid-vitamin E, but also gives the polyglutamic acid-vitamin E amphiphilic conjugate certain antioxidant properties and amphiphilic properties; The invention can obtain polyglutamic acid-vitamin E amphiphilic conjugates with different hydrophilic-lipophilic balance values by adjusting the ratio of polyglutamic acid and vitamin E, so as to meet the requirements of two different emulsification systems, namely, water-in-oil and oil-in-water.
[0017] In summary, the polyglutamic acid-vitamin E amphiphilic conjugate of the present invention exhibits wider applicability in a variety of emulsification systems and can exhibit more excellent antioxidant properties, so that it has broad application potential and broad development space in the antioxidant fields of crop production, health products, pharmaceutical excipients, feed additives, cosmetics and functional foods.
[0018] The present invention also provides a method for preparing the polyglutamic acid-vitamin E amphiphilic conjugate described in the above technical scheme, comprising the following steps: firstly mixing polyglutamic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, p-dimethylaminopyridine and a first solvent, and then performing a condensation reaction to obtain an activation solution; secondly mixing a vitamin E solution and the activation solution, and then performing an esterification reaction to obtain vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate. The method is simple to operate. Furthermore, the present invention can also achieve the regulation of the vitamin E grafting rate in the conjugate by adjusting the molar ratio of polyglutamic acid, vitamin E, and the condensation agent 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride in the formula. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The present invention provides a reaction process for preparing the polyglutamic acid-vitamin E amphiphilic conjugate; Figure 2 The γ-PGluH prepared in Example 1 1 H NMR spectra; Figure 3 The α-PGluH prepared in Example 11 1 H NMR spectra; Figure 4 For VE 1 H NMR spectra; Figure 5 The polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1 1 H NMR spectra; Figure 6 The polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 11 1 H NMR spectra; Figure 7 This is a physical picture of the aqueous solution of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1, Example 8 and Example 10; Figure 8 The particle size distribution curves of the aqueous solutions of the polyglutamic acid-vitamin E amphiphilic conjugates prepared in Example 1, Example 8 and Example 10; Fig. 9 These are SEM and TEM images of the polyglutamic acid-vitamin E amphiphilic conjugates prepared in Example 1 and Example 8; Fig.10 The appearance of the PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, and the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 10 in different solvents; Fig.11 The micelle concentration and I of the polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 8 to 10 are 373 / I 384 The curve relationship diagram of the value; Fig.12 It is a bar graph of cell viability at various concentrations of γ-PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Examples 8 to 10, and vitamin E polyethylene glycol succinate (TPGS); Fig.13It is a graph showing the antioxidant properties of γ-PGluH described in Example 1, the polyglutamate-vitamin E amphiphilic conjugate described in Example 1, the polyglutamate-vitamin E amphiphilic conjugate described in Example 7, the polyglutamate-vitamin E amphiphilic conjugate described in Example 9, the polyglutamate-vitamin E amphiphilic conjugate described in Example 10, VE and TPGS. DETAILED DESCRIPTION
[0020] The present invention provides a polyglutamic acid-vitamin E amphiphilic conjugate having a structure shown in Formula 1 or Formula 2: Formula 1, Formula 2; In Formula 1 and Formula 2, m+n=15~2300, and n is any natural number between 1 and 100.
[0021] In the present invention, the grafting rate of vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate is preferably 0.1-25%.
[0022] The present invention also provides a method for preparing the polyglutamic acid-vitamin E amphiphilic conjugate described in the above technical solution, comprising the following steps: The polyglutamic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, p-dimethylaminopyridine and the first solvent are first mixed and then subjected to a condensation reaction to obtain an activation solution; The vitamin E solution and the activation solution are mixed for a second time, and an esterification reaction is performed to obtain the vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate.
[0023] In the present invention, unless otherwise specified, all preparation raw materials are commercially available products well known to those skilled in the art.
[0024] The invention first mixes polyglutamic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, p-dimethylaminopyridine and a first solvent, and then performs a condensation reaction to obtain an activation solution.
[0025] In the present invention, the polyglutamic acid is preferably γ-polyglutamic acid or α-polyglutamic acid. When the polyglutamic acid is γ-polyglutamic acid, the structure of the product obtained after the reaction is shown in Formula 1; when the polyglutamic acid is α-polyglutamic acid, the structure of the product obtained after the reaction is shown in Formula 2. In the present invention, the γ-polyglutamic acid is preferably prepared by a microbial fermentation method. The present invention does not have any special restrictions on the process of the microbial fermentation method, and the process well known to those skilled in the art can be used. In the present invention, the α-polyglutamic acid is preferably prepared by a chemical synthesis method. The present invention does not have any special restrictions on the process of the chemical synthesis method, and the process well known to those skilled in the art can be used.
[0026] In the present invention, since the γ-polyglutamic acid prepared by the microbial fermentation method is a γ-polyglutamate salt, the γ-polyglutamic acid prepared by the microbial fermentation method is preferably acid-treated, dialyzed and freeze-dried in sequence before the first mixing. The acid treatment preferably uses concentrated hydrochloric acid with a mass concentration of 36% to 38%, and the pH of the γ-polyglutamic acid obtained after the acid treatment is preferably 2 to 4. The temperature of the acid treatment is preferably 25 to 30 ° C, and the time of the acid treatment is preferably 2h; the acid treatment is preferably carried out under stirring conditions, and the present invention has no special restrictions on the stirring process, and the process well known to those skilled in the art can be used; in the present invention, the dialysis preferably uses a dialysis bag with a molecular weight cutoff of 1000Da, and dialyzes with distilled water for 48h; the present invention has no special restrictions on the freeze-drying process, and the process well known to those skilled in the art can be used. In the present invention, the molecular weight of the γ-polyglutamic acid is preferably 2000 to 300000Da; the molecular weight of the α-polyglutamic acid is preferably 2000 to 10000Da.
[0027] In the present invention, the first solvent preferably includes one or more of dichloromethane, N,N'-dimethyldiamide and dimethyl sulfoxide. When the first solvent is two or more of the above specific options, the present invention has no special limitation on the ratio of the above specific substances, and they can be mixed in any ratio.
[0028] The present invention does not have any special limitation on the mixing process, and the mixing process may be carried out by a process well known to those skilled in the art and sufficient dissolution may be ensured.
[0029] In the present invention, the concentration of polyglutamic acid in the mixed solution obtained by the first mixing is preferably 0.05~7.5mmol / L, more preferably 2~6mmol / L; the concentration of carboxyl groups in polyglutamic acid in the mixed solution obtained by the first mixing is preferably 112~115mmol / L, more preferably 113~114mmol / L; the molar ratio of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to polyglutamic acid is preferably (0.3~1.2):1, more preferably (0.5~1.0):1; the molar ratio of p-dimethylaminopyridine to carboxyl groups in polyglutamic acid is preferably (0.3~1):1, more preferably (0.4~0.8):1.
[0030] In the present invention, the role of the 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is condensation, and the role of the p-dimethylaminopyridine is catalysis.
[0031] In the present invention, the temperature of the condensation reaction is preferably room temperature, and the time is preferably 1 to 4 hours, more preferably 2 to 3 hours. In the present invention, the condensation reaction is preferably carried out in a protective atmosphere, and the protective atmosphere is preferably nitrogen.
[0032] After obtaining the activation solution, the present invention secondly mixes the vitamin E solution and the activation solution to carry out an esterification reaction to obtain the vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate.
[0033] In the present invention, the concentration of vitamin E in the vitamin E solution is preferably 50-500 mmol / L, more preferably 200-300 mmol / L; the vitamin E in the vitamin E solution is preferably D-α-vitamin E. In the present invention, the solvent in the vitamin E solution preferably includes one or more of dichloromethane, N,N'-dimethyldiamide and dimethyl sulfoxide. When the solvent is two or more of the above specific options, the present invention has no special restrictions on the ratio of the above specific substances, and they can be mixed in any ratio.
[0034] In the present invention, the molar ratio of the hydroxyl group in the vitamin E in the vitamin E solution to the carboxyl group in the polyglutamic acid in the mixed solution obtained by the first mixing is preferably (0.3-2):1, and more preferably (0.5-1):1. In an embodiment of the present invention, the concentration of vitamin E in the vitamin E solution is specifically 69 mmol / L, 114 mmol / L, 115 mmol / L, 225 mmol / L, 226 mmol / L, 228 mmol / L, 229 mmol / L, 456 mmol / L, 458 mmol / L, and the molar ratio of the hydroxyl group in the vitamin E in the vitamin E solution to the carboxyl group in the polyglutamic acid in the mixed solution obtained by the first mixing is specifically 0.3:1, 0.5:1, 1:1 and 2:1.
[0035] The present invention has no special limitation on the second mixing process, and it can be carried out by a process well known to those skilled in the art. In an embodiment of the present invention, the second mixing is to add the vitamin E solution to the activation solution.
[0036] In the present invention, the esterification reaction is preferably carried out under light-proof conditions, the temperature of the esterification reaction is preferably 25-30°C, more preferably 30°C, and the time is preferably 24-48h. In an embodiment of the present invention, the temperature of the esterification reaction is specifically 30°C, and the time is specifically 24h.
[0037] After the esterification reaction is completed, the present invention also preferably includes the first precipitation, the first centrifugation, the first redissolution, the second precipitation, the second centrifugation, the first drying, the second redissolution, the dialysis, the third centrifugation and the second drying in sequence. In the present invention, the precipitants used in the first precipitation and the second precipitation are preferably icy ether. The present invention does not have any special restrictions on the processes of the first centrifugation, the second centrifugation and the third centrifugation, and can be carried out using processes well known to those skilled in the art. In the present invention, the redissolution used in the first redissolution is preferably methanol. In the present invention, the redissolution used in the second redissolution is preferably distilled water. In the present invention, the dialysis is preferably to mix the crude product obtained by the suction filtration with the second solvent and then put it into a dialysis bag with a molecular weight cutoff of 1000~3500Da, and dialyze with distilled water for 24~48h; the second solvent is preferably one or more of distilled water, dimethyl sulfoxide and methanol. When the second solvent is two or more of the above-mentioned specific selections, the present invention does not have any special restrictions on the ratio of the above-mentioned specific substances, and can be mixed in any ratio. In the present invention, the first drying is preferably vacuum drying, and the second drying is preferably freeze drying. The present invention does not have any special limitation on the freeze drying process, and the process well known to those skilled in the art can be used.
[0038] The present invention also provides the use of the polyglutamic acid-vitamin E amphiphilic conjugate described in the above technical solution or the polyglutamic acid-vitamin E amphiphilic conjugate prepared by the preparation method described in the above technical solution in the field of anti-oxidation or the field of drug-loaded nano micelles.
[0039] In the present invention, the antioxidant field is preferably the field of cosmetics or functional foods; the drug-loaded nanomicelle field is preferably the field of pharmaceutical excipients.
[0040] In the present invention, when the polyglutamic acid-vitamin E amphiphilic conjugate is used in the field of anti-oxidation, the grafting rate of vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate is preferably 2.5-13.5%.
[0041] In the present invention, when the polyglutamic acid-vitamin E amphiphilic conjugate is used in the field of drug-loaded nanomicelles, the grafting rate of vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate is preferably 2.5-10%.
[0042] The polyglutamic acid-vitamin E amphiphilic conjugate provided by the present invention and its preparation method and application are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0043] Example 1 Commercially available sodium γ-polyglutamic acid (labeled molecular weight of 10,000 Da) was prepared into an aqueous solution with a concentration of 50 mg / mL, and its pH was adjusted to between 2.61 and 3.66 using concentrated hydrochloric acid with a mass concentration of 36% to 38%, and stirred at 25°C for 2 hours to obtain flocculent precipitation. The reaction solution was then placed in a dialysis bag with a molecular weight cutoff of 1,000 Da, dialyzed with distilled water for 48 hours, and then freeze-dried to obtain γ-polyglutamic acid (γ-PGluH, tested by gel permeation chromatography (GPC), with a molecular weight of 15,700 Da) without sodium salt. like Figure 1 According to the reaction process shown in (a), 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl groups, calculated by the following formula: molar number of carboxyl groups = (mass of polyglutamic acid / molecular weight of polyglutamic acid) / degree of polymerization of polyglutamic acid; degree of polymerization of polyglutamic acid = Int (molecular weight of polyglutamic acid / molecular weight of glutamic acid)), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.440 g, 2.29 mmol) and p-dimethylaminopyridine (DMAP, 0.280 g, 2.29 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, the gas in the bottle was replaced with nitrogen three times, and then the system was stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0044] VE (0.986 g, 2.29 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, glacial ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with glacial ether and centrifuged, and the obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days, and the retained liquid after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE) having a structure shown in Formula 1, with a yield of 59%, and the yield was calculated by the following formula: yield = mass of the obtained product / (polyglutamic acid added amount + vitamin E added amount).
[0045] Example 2 Referring to Example 1, the difference is that dichloromethane (DCM) is replaced by dimethyl sulfoxide (DMSO), and a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 59%) having a structure shown in Formula 1 is prepared.
[0046] Example 3 Referring to Example 1, the difference is that dichloromethane (DCM) is replaced by N,N'-dimethylformamide (DMF) to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 41%) having a structure shown in Formula 1.
[0047] Example 4 Referring to Example 1, the difference is that: the commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 2000 Da) and the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by gel permeation chromatography (GPC), molecular weight of 2000 Da); 0.3 g of the γ-PGluH (containing 2.25 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.431 g, 2.25 mmol) and p-dimethylaminopyridine (DMAP, 0.275 g, 2.25 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activation solution.
[0048] VE (0.968 g, 2.25 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 54%) having a structure shown in Formula 1.
[0049] Example 5 Referring to Example 1, the difference is that: the commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 300,000 Da) and the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 305,000 Da); 0.3 g of the γ-PGluH (containing 2.26 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.433 g, 2.26 mmol) and p-dimethylaminopyridine (DMAP, 0.276 g, 2.26 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0050] VE (0.973 g, 2.26 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 49%) having a structure shown in Formula 1.
[0051] Example 6 Referring to Example 1, commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 10,000 Da), the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 15,700 Da); 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.527 g, 2.75 mmol) and p-dimethylaminopyridine (DMAP, 0.280 g, 2.29 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0052] VE (0.986 g, 2.29 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 53%) having a structure shown in Formula 1.
[0053] Example 7 Referring to Example 1, commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 10,000 Da), the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 15,700 Da); 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.440 g, 2.29 mmol) and p-dimethylaminopyridine (DMAP, 0.280 g, 2.29 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0054] VE (1.972 g, 4.58 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 51%) having a structure shown in Formula 1.
[0055] Example 8 Referring to Example 1, commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 10,000 Da), the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 15,700 Da); 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.440 g, 2.29 mmol) and p-dimethylaminopyridine (DMAP, 0.280 g, 2.29 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0056] VE (0.493 g, 1.15 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 54%) having a structure shown in Formula 1.
[0057] Example 9 Referring to Example 1, the difference is that: the commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 10,000 Da) and the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 15,700 Da); 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.420 g, 1.15 mmol) and p-dimethylaminopyridine (DMAP, 0.140 g, 1.15 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activation solution.
[0058] VE (0.493 g, 1.15 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 52%) having a structure shown in Formula 1.
[0059] Example 10 Referring to Example 1, the difference is that: the commercially available sodium salt of γ-polyglutamic acid (labeled molecular weight of 10,000 Da) and the obtained sodium salt-removed γ-polyglutamic acid (γ-PGluH, tested by GPC, molecular weight of 15,700 Da); 0.3 g of the γ-PGluH (containing 2.29 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.132 g, 0.69 mmol) and p-dimethylaminopyridine (DMAP, 0.084 g, 0.69 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0060] VE (0.296 g, 0.69 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (γ-PGluVE, yield 47%) having a structure shown in Formula 1.
[0061] Embodiment 11 like Figure 1According to the reaction process shown in (b), 0.3 g of chemically synthesized α-PGluH (tested by GPC, molecular weight of 10000 Da, containing 2.28 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.437 g, 2.28 mmol) and p-dimethylaminopyridine (DMAP, 0.279 g, 2.28 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0062] VE (0.982 g, 2.28 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (α-PGluVE, yield 49%) having a structure shown in Formula 2.
[0063] Example 12 like Figure 1 According to the reaction process shown in (b), 0.3 g of chemically synthesized α-PGluH (tested by GPC, molecular weight of 2000 Da, containing 2.28 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.437 g, 2.28 mmol) and p-dimethylaminopyridine (DMAP, 0.279 g, 2.28 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, the gas in the bottle was replaced with nitrogen three times, and then the system was stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0064] VE (0.982 g, 2.28 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (α-PGluVE, yield 43%) having a structure shown in Formula 2.
[0065] Embodiment 13 like Figure 1 According to the reaction process shown in (b), 0.3 g of chemically synthesized α-PGluH (molecular weight of 10,000 Da, containing 2.28 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.437 g, 2.28 mmol) and p-dimethylaminopyridine (DMAP, 0.279 g, 2.28 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0066] VE (1.964 g, 4.56 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (α-PGluVE, yield 45%) having a structure shown in Formula 2.
[0067] Embodiment 14 like Figure 1 According to the reaction process shown in (b), 0.3 g of chemically synthesized α-PGluH (molecular weight of 10,000 Da, containing 2.28 mmol of carboxyl group), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.437 g, 2.28 mmol) and p-dimethylaminopyridine (DMAP, 0.279 g, 2.28 mmol) were placed in a 50 mL Schlenk bottle, 20 mL of dichloromethane (DCM) was added, and the gas in the bottle was replaced with nitrogen three times. The system was then stirred at room temperature for condensation reaction for 1 hour to obtain an activated solution.
[0068] VE (0.491 g, 1.14 mmol) and 10 mL of DCM were dissolved in a 15 mL Schlenk bottle to obtain a VE solution; The VE solution was slowly added dropwise to the above-mentioned activation solution to obtain a reaction solution, and the reaction solution was reacted at room temperature in the dark for 24 hours. After the reaction was completed, icy ether was added to precipitate the product, and the solid obtained after centrifugation was dissolved with a trace amount of methanol, precipitated with icy ether and centrifuged again. The obtained solid was vacuum dried, dissolved with a trace amount of distilled water and dialyzed for 2 days. The retained solution after dialysis was freeze-dried to prepare a polyglutamic acid-vitamin E amphiphilic conjugate (α-PGluVE, yield 49%) having a structure shown in Formula 2.
[0069] Test Example 1 H NMR spectrum ( 1 H NMR) determination: 5 mg of the γ-PGluH prepared in Example 1 and the α-PGluH prepared in Example 11 were dissolved in 1 mL of deuterated water, and 5 mg of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1 and Example 11 were dissolved in 1 mL of deuterated dimethyl sulfoxide, and then the dissolved samples were transferred to nuclear magnetic resonance tubes and tested in a nuclear magnetic resonance spectrometer (working frequency of 400 MHz) to obtain the corresponding materials. 1 H NMR spectra, and the spectra were analyzed using Mestrenova software; in Figure 2 The γ-PGluH prepared in Example 1 1 H NMR spectrum, Figure 3 The α-PGluH prepared in Example 11 1 H NMR spectrum, Figure 4 For VE 1 H NMR spectrum, Figure 5 The polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1 1 H NMR spectrum, Figure 6 The polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 11 1 H NMR spectrum, by Figure 2-Figure 6It can be seen that there is not much difference in the positions of the characteristic peaks of γ-type and α-type PGluH and γ-type and α-type PGluVE. In the spectrum, 4.70ppm corresponds to the D2O solvent peak, 2.50ppm corresponds to the d6-DMSO solvent peak, and 3.25ppm corresponds to H2O. The characteristic peak positions in (γ- / α-)PGluH are assigned to: 1.64~2.07ppm (e, 2H), 2.27ppm (d, 2H), 4.04ppm (c, 1H), and the peak area integral of hydrogen (H) at the c, d and e positions is approximately 1:2:2. The characteristic peak positions in VE are assigned to: 0.75~0.82ppm (p and q, 12H). After the (γ- / α-)PGluH was grafted with VE groups, H at the p and q positions of VE appeared at 0.75-0.82ppm, and the peak signal at 1.64-2.07ppm was enhanced, and H at g, f, and h of VE appeared, proving that (γ- / α-)PGluVE was successfully synthesized. Based on the peak area of H at the c position and the peak area of H at the p and q positions in the 1H-NMR graph of PGluVE, the grafting rate of the VE group was calculated using the following formula, and the results are shown in Table 1.
[0070]
[0071] Table 1 VE grafting rate of polyglutamic acid-vitamin E conjugates
[0072] As shown in Table 1, by changing the molar ratio of the carboxyl group of PGluH, EDCI, DMAP and VE in the experiment, a series of PGluVE grafting rates can be obtained, and the grafting rates range from 1.3% to 25%.
[0073] Appearance and particle size determination of polyglutamic acid-vitamin E amphiphilic conjugate aqueous solution: 15 mg of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1, Example 8 and Example 10 were respectively dissolved in 1 mL of ultrapure water to prepare a 15 mg / mL aqueous solution, and its appearance was observed. Figure 7 The actual picture of the aqueous solution of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1, Example 8 and Example 10 is Figure 7 It can be seen that with the increase of PGluVE grafting rate, the turbidity of the aqueous solution gradually increased; The particle size of the aqueous solution of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in the above Examples 1, 8 and 10 at 25° C. was measured using a Malvern particle size analyzer. Figure 8 is the particle size distribution curve of the aqueous solution of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 1, Example 8 and Example 10, Figure 8It can be seen that when the PGluVE grafting rate is 2.5%, the particle size is 13.0nm; when the PGluVE grafting rate is 7.5%, two particle size peaks appear, 30.6nm and 211.4nm respectively; when the PGluVE grafting rate is 13.5%, the particle size is 396.4nm. It can be seen that with the increase of the grafting rate, the hydrophobicity of PGluVE gradually increases and the particle size gradually increases.
[0074] SEM and TEM determination: 5 mg of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 8 and Example 10 were respectively dissolved in 2.5 mL of ultrapure water to prepare a 2 mg / mL aqueous solution; the aqueous solution was dropped on a silicon wafer with a pipette gun, and placed in a vacuum drying oven to dry overnight. After the dried sample was sprayed with gold for 30 seconds with an ion sputtering instrument, the silicon wafer was attached to a conductive carbon film glue, and observed and photographed with a SEM; 5 mg of the polyglutamic acid-vitamin E amphiphilic conjugate prepared in Example 8 and Example 10 were respectively dissolved in 2.5 mL of ultrapure water to prepare a 2 mg / mL aqueous solution; the aqueous solution was dropped onto the carbon film copper sheet with a pipette, the excess liquid was absorbed with filter paper, and the solution was placed in a vacuum drying oven for overnight drying, and then observed and photographed with a TEM; Fig. 9 The SEM and TEM images of the polyglutamic acid-vitamin E amphiphilic conjugates prepared in Examples 1 and 8, wherein a is the SEM image of Example 8, b is the SEM image of Example 1, a' is the TEM image of Example 8, and b' is the TEM image of Example 1; Fig. 9 It can be seen that most of the PGluVE particles are spherical particles of about 10 nm. However, with the increase of grafting rate, the number of PGluVE aggregates of 200 to 400 nm can be observed to increase, indicating that the hydrophobicity of PGluVE increases.
[0075] Dissolution phenomenon in different solvents: 15 mg of PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, and the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 16 were added to 1 mL of different solvents (DMSO (dimethyl sulfoxide), H2O (water), MeOH (methanol), EtOH (ethanol), Gl (glycerol), DCM (dichloromethane), DMF (dimethylformamide), and IPA (isopropanol)) and dissolved, and their appearance was observed. Fig.10 The appearance of the PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, and the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 10 in different solvents is shown in FIG. Fig.10It can be seen that when PGluH is connected to VE, its solubility in organic solvents increases significantly. As the grafting rate increases, the solubility of the polyglutamic acid-vitamin E amphiphilic conjugate in water decreases. When the grafting rate of VE increases to 13.5%, the polyglutamic acid-vitamin E amphiphilic conjugate can be completely dissolved in methanol, DMSO and glycerol, which also shows that the hydrophilic and lipophilic properties of the polyglutamic acid-vitamin E amphiphilic conjugate can be adjusted by adjusting the grafting rate of VE.
[0076] Hydrophile-lipophile balance value: The HLB of the known emulsified peanut oil was adjusted to 13.93, and different proportions of Span 80 or Tween 80 (Span 80 was used when the grafting rate was 2.5% and 3.5%, and tween 80 was used when the grafting rate was 7.5%, 10% and 13.5%) and 1 mL of aqueous solution of γ-PGluVE with different grafting rates were prepared. The mass ratio of Span 80 or Tween 80 to the polyglutamic acid-vitamin E amphiphilic conjugate with different grafting rates was 0.5:9.5~9.5:0.5, and with a mass ratio of 0.5 as an interval, Examples 1 and Examples 7~10 were selected as samples (i.e., the grafting rates were 2.5%, 3.5%, 7.5%, 10% and 13.5%). In the whole system, the mass proportion of Span 80 or Tween 80 plus polyglutamic acid-vitamin E amphiphilic conjugates with different grafting ratios is 5%, the mass proportion of peanut oil is 10%, and the mass proportion of distilled water is 85%. After the sample is vortexed for 1 minute using a vortexer, the sample is emulsified with an ultrasonic emulsifier for 1 minute. After the obtained emulsion is left to stand overnight, the stability of the emulsion is compared and observed: When the emulsion is uniform and stable, the following formula (HLB 混合物 = Mass fraction of A × HLB A + mass fraction of B × HLB B , A is γ-PGluVE with different grafting rates, B is Span 80 or Tween 80), the HLB values of polyglutamic acid-vitamin E amphiphilic conjugates with different grafting rates can be obtained, and the results are shown in Table 2: Table 2 Hydrophile-lipophile balance (HLB) of polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 7 to 10
[0077] As shown in Table 2, by adjusting the ratio of polyglutamic acid to vitamin E in the reaction, polyglutamic acid-vitamin E amphiphilic conjugates with a series of hydrophilic-lipophilic balance values can be prepared to meet the needs of two different emulsification systems: oil-in-water and water-in-oil.
[0078] Critical micelle concentration (CMC): The critical micelle concentration of the polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 8 to 10 was determined by a fluorescent probe method. The specific process was as follows: 5 mg of the polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 7 to 10 were weighed, dissolved in 5 mL of ultrapure water, and then transferred to a 5 mL volumetric flask, and ultrapure water was added to the volume to prepare a mother solution of 1000 μg / mL, and then 500 μg / mL, 250 μg / mL, 100 μg / mL, 50 μg / mL, 25 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 4 μg / mL, 3 μg / mL, 2 μg / mL, 1 μg / mL, 0.5 μg / mL and 0.3 μg / mL sample solutions were prepared respectively; Pyrene was used as the fluorescent probe and acetone was used as the solvent to prepare the solution at a concentration of 5×10 -5 mol / L pyrene solution; Take 40 μL of each with a concentration of 5×10 -5 mol / L pyrene solution was placed in 10mL centrifuge tubes, a total of 14 tubes. At room temperature, after the acetone in the centrifuge tubes evaporated naturally, 4mL of the above sample solution was added to each tube. Ultrasonication was performed for 15min, and oscillation was performed in a 65℃ water bath for 2h. After the sample was allowed to stand at room temperature to balance, the fluorescence intensity of each sample was measured (fluorescence measurement conditions: λ ex =333nm,λ em =350~550nm, slit width is 5nm, sample pool thickness is 1cm), record the fluorescence absorbance values of the samples at 373nm and 384nm, and calculate the fluorescence intensity ratio of each sample at 373nm and 384nm (I 373 / I 384 ) value. The Boltzmann equation was used to fit the concentration and I 373 / I 384 The value curve, such as Fig.11 (in Fig.11 The micelle concentration and I of the polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 8 to 10 are 373 / I 384 The CMC value of the sample is obtained, and the results are shown in Table 3: Table 3 Critical micelle concentration of polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 1 and 8 to 10
[0079] Depend on Fig.11 As shown in Table 3, with the increase of grafting rate, the hydrophobicity of polyglutamic acid-vitamin E amphiphilic conjugate becomes stronger and it is easier to form micelles.
[0080] Biological toxicity: Human skin fibroblasts (HFF-1) were cultured in an incubator at 37°C and 5% CO2. Cells in the logarithmic phase were removed and plated at 5×10 cells per well. 3 The cells were inoculated in a 96-well plate, with an inoculation volume of 200μL per well, and incubated for 24 hours until the cells adhered to the wall. 200μL was aspirated into the 96-well plate and incubated for 5 minutes and then discarded, and 180μL of culture medium and 20μL of the prepared sample to be tested were added, and the cells were incubated for 24 hours under the same conditions. Among them, γ-PGluH described in Example 1, polyglutamic acid-vitamin E amphiphilic conjugates described in Examples 8 to 10, and vitamin E polyethylene glycol succinate (TPGS) were selected as samples, that is, polyglutamic acid-vitamin E amphiphilic conjugates and TPGS with grafting rates of 2.5%, 3.5% and 7.5%, respectively. In the experiment, the samples were all soluble in the culture medium, and the concentrations of the samples were 50μg / mL, 100μg / mL, 500μg / mL and 1000μg / mL, respectively.
[0081] After the incubation, discard the culture medium containing the sample, draw 200μL into the 96-well plate, incubate for 5 minutes, then discard, add 180μL culture medium and 20μL MTT solution (MTT concentration is 5mg / mL, i.e. 0.5% MTT) to each well, continue incubation for 4h and then terminate the culture. Carefully aspirate the culture supernatant in the well, add 150μL DMSO to each well, and shake on a shaker for 10min. Use an ELISA reader to measure the absorbance of each well at a wavelength of 490nm, record the results, and draw a bar graph of cell survival rate of different samples at each concentration (such as Fig.12 ), by Fig.12 It can be seen that TPGS has a high cytotoxicity at a concentration of 50μg / mL. However, when the grafting rate of polyglutamic acid-vitamin E amphiphilic conjugate is 2.5% to 13.5%, its IC 50 All of them were greater than 1 mg / mL, indicating that PGluVE was basically safe and non-toxic.
[0082] Antioxidant property: Take the γ-PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 7, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 9, and the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 10, VE and TPGS to prepare aqueous solutions of corresponding concentrations (the concentration is calculated according to the 2mM VE equivalent). Take 10μL of the sample to be tested and mix it with 90μL of 1mM DPPH free radical solution. After incubation for 30min under light-proof conditions, measure the absorbance of the mixed solution at a wavelength of 517nm by an enzyme marker to evaluate the scavenging ability of the sample for DPPH free radicals (scavenging rate = (1-blank control absorbance / sample absorbance) × 100%), thereby reflecting its antioxidant property. Fig.13The antioxidant performance graphs of γ-PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 7, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 9, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 10, VE and TPGS are shown in FIG. Fig.13 It can be seen that the polyglutamic acid-vitamin E amphiphilic conjugate has stronger antioxidant capacity than TPGS, among which the polyglutamic acid-vitamin E amphiphilic conjugate with a grafting rate of 2.5% (Example 10) has better antioxidant activity.
[0083] Solubilization ability test: 1) Solubilization ability for ibuprofen: Establishment of standard curve: Accurately weigh 5 mg of ibuprofen into a 25 mL volumetric flask, add chromatographic pure MeOH to dissolve, and then dilute to prepare ibuprofen solutions with concentrations of 0.5 µg / mL, 1 µg / mL, 2.5 µg / mL, 5 µg / mL, 10 µg / mL, 20 µg / mL, 25 µg / mL, 50 µg / mL and 100 µg / mL. Chromatographic conditions: chromatographic column: C18 (250 mm × 4.6 mm, 5 μm); mobile phase: acetonitrile: sodium acetate buffer (pH = 2.0) = 60:40; detection wavelength: 275 nm, column temperature: 40.0 ° C, flow rate: 1.0 mL / min, injection volume: 20 μL, detection time is 20 min, isocratic elution.
[0084] 1 mg of γ-PGluH described in Example 1, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 10, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 9, the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 7, and the polyglutamic acid-vitamin E amphiphilic conjugate described in Example 14 were respectively dissolved in 1 mL of distilled water, shaken at room temperature for 4 h, 25 μL of a 50 mg / mL ibuprofen dimethyl sulfoxide solution was added dropwise, and after shaking at 120 rpm for 12 h at room temperature, centrifuged at 5000 rpm for 5 min, the supernatant was filtered through a 3 μm filter membrane to obtain 0.5 mL of an ibuprofen solubilized aqueous solution (the solubilized aqueous solution was used as a sample); 25 μL of a 50 mg / mL ibuprofen dimethyl sulfoxide solution was added dropwise, and the mixture was shaken at 120 rpm for 12 h at room temperature. The mixture was centrifuged at 5000 rpm for 5 min, and the supernatant was filtered through a 3 μm filter membrane to obtain 0.5 mL of an ibuprofen solubilized aqueous solution (the solubilized aqueous solution was used as a sample); 25 μL of a 50 mg / mL ibuprofen dimethyl sulfoxide solution was added dropwise, and the mixture was stirred for 2 hours at room temperature. mL of ibuprofen dimethyl sulfoxide solution was added dropwise to 1 mL of distilled water, and after shaking at 120 rpm for 12 hours at room temperature, the solution was centrifuged at 5000 rpm for 5 minutes, and the supernatant was filtered through a 3 μm filter membrane to obtain 0.5 mL of ibuprofen solubilized aqueous solution (the solubilized aqueous solution was used as comparative example 1); 10 mg of vitamin E polyethylene glycol succinate (TPGS) was dissolved in 1 mL of distilled water, shaken at room temperature for 4 hours, and 25 μL of ibuprofen dimethyl sulfoxide solution with a concentration of 50 mg / mL was added dropwise, and after shaking at 120 rpm for 12 hours at room temperature, the solution was centrifuged at 5000 rpm for 5 minutes, and the supernatant was filtered through a 3 μm filter membrane to obtain 0.5 mL of ibuprofen solubilized aqueous solution (the solubilized aqueous solution was used as comparative example 2); The above ibuprofen solubilization aqueous solution was freeze-dried, and then re-dissolved with chromatographically pure MeOH. After ultrasonication for 15 minutes, the solution was filtered through a 0.45 μm membrane and analyzed by HPLC. The solubilization results are shown in Table 4.
[0085] Table 4 Solubility of ibuprofen in 1 mg / mL TPGS and polyglutamic acid-vitamin E amphiphilic conjugates with different grafting ratios in aqueous solution
[0086] Note: DMSO can be replaced by methanol (MeOH), DCM or tetrahydrofuran (THF) as organic solvents. Solubilization capacity of carvedilol: Establishment of standard curve: Accurately weigh 5 mg of carvedilol into a 25 mL volumetric flask, add chromatographic grade methanol (MeOH) to dissolve, and then dilute to prepare carvedilol solutions with concentrations of 0.5 µg / mL, 1 µg / mL, 2.5 µg / mL, 5 µg / mL, 10 µg / mL, 20 µg / mL, 25 µg / mL, 50 µg / mL, 100 µg / mL, 200 µg / mL and 400 ug / mL. Chromatographic conditions are: chromatographic column: C18 (250 mm × 4.6 mm, 5 μm); mobile phase: 35% acetonitrile, 65% 0.02 mol / L KH2PO4 solution (adjusted to pH 3.5 with phosphoric acid; detection wavelength: 241 nm, column temperature: 25 ° C, flow rate: 1 mL / min, injection volume: 10 µL, detection time: 20 min, isocratic elution.
[0087] 1 mg of γ-PGluH described in Example 1, 10 polyglutamic acid-vitamin E amphiphilic conjugate described in Example 1, and 14 polyglutamic acid-vitamin E amphiphilic conjugate were dissolved in 1 mL of distilled water, shaken at room temperature for 4 h, and 25 μL of a 20 mg / mL carvedilol dimethyl sulfoxide solution was added dropwise. After shaking at 120 rpm for 12 h at room temperature, the mixture was centrifuged at 5000 rpm for 5 min, and the supernatant was filtered through a 3 μm filter membrane to obtain 0.5 mL of a solubilized aqueous solution of carvedilol (the solubilized aqueous solution was used as a sample); 25 μL of a 20 mg / mL carvedilol dimethyl sulfoxide solution was added dropwise to 1 mL of distilled water. After shaking at 120 rpm for 12 hours at room temperature, centrifuge at 5000 rpm for 5 minutes, take the supernatant and filter through a 3 μm filter membrane to obtain 0.5 mL of a solubilized aqueous solution of carvedilol (the solubilized aqueous solution is used as comparative example 1); dissolve 10 mg of vitamin E polyethylene glycol succinate (TPGS) in 1 mL of distilled water, shake at room temperature for 2 to 4 hours, dropwise add 25 μL of a 20 mg / mL carvedilol dimethyl sulfoxide solution, shake at 120 rpm for 12 to 24 hours at room temperature, centrifuge at 5000 rpm for 5 minutes, take the supernatant and filter through a 3 μm filter membrane to obtain 0.5 mL of a solubilized aqueous solution of carvedilol (the solubilized aqueous solution is used as comparative example 2); The carvedilol solubilization aqueous solution was freeze-dried and then re-dissolved with chromatographically pure MeOH. After ultrasonication for 15 min, the solution was filtered through a 0.45 μm membrane and analyzed by HPLC. The solubilization results are shown in Table 5.
[0088] Table 5 Solubility of carvedilol in aqueous solution of 1 mg / mL TPGS and polyglutamic acid-vitamin E amphiphilic conjugates with different grafting ratios
[0089] Note: The organic solvent can be replaced by methanol (MeOH), DCM or tetrahydrofuran (THF) instead of DMSO.
[0090] Comparing the above solubilization results, the polyglutamic acid-vitamin E amphiphilic conjugate is more suitable for insoluble substances that are easily dissociated and dissolved under acidic conditions due to the local weak acidic environment formed by its free carboxyl group. The solubilization effect of the polyglutamic acid-vitamin E amphiphilic conjugate on insoluble substances that rely on acidic conditions is significantly better than that of TPGS. Among them, the polyglutamic acid-vitamin E amphiphilic conjugate with a grafting rate of 2.5% has a more obvious solubilization effect on insoluble substances because of its larger HLB value, especially γ-PGluVE.
[0091] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A polyglutamic acid-vitamin E amphiphilic conjugate, characterized in that: It has a structure shown in Formula 1 or Formula 2: Formula 1, Formula 2; In Formula 1 and Formula 2, m+n=15~2300, and n is any natural number between 1 and 100.
2. The polyglutamic acid-vitamin E amphiphilic conjugate according to claim 1, characterized in that: The grafting rate of vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate is 0.1-25%.
3. The method for preparing the polyglutamic acid-vitamin E amphiphilic conjugate according to claim 1 or 2, characterized in that: The following steps are involved: The polyglutamic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, p-dimethylaminopyridine and the first solvent are first mixed and then subjected to a condensation reaction to obtain an activation solution; The vitamin E solution and the activation solution are mixed for a second time, and an esterification reaction is performed to obtain the vitamin E in the polyglutamic acid-vitamin E amphiphilic conjugate.
4. The preparation method according to claim 3, characterized in that: The polyglutamic acid is γ-polyglutamic acid or α-polyglutamic acid; The number average molecular weight of the γ-polyglutamic acid is 2000-300000Da; the number average molecular weight of the α-polyglutamic acid is 2000-10000Da.
5. The preparation method according to claim 3, characterized in that: The concentration of polyglutamic acid in the mixed solution obtained by the first mixing is 0.05-7.5 mmol / L, and the concentration of carboxyl groups in the polyglutamic acid in the mixed solution obtained by the first mixing is 112-115 mmol / L; The molar ratio of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to polyglutamic acid is (0.3-1.2):1; The molar ratio of the p-dimethylaminopyridine to the carboxyl group in polyglutamic acid is (0.3-1):
1.
6. The preparation method according to claim 3, characterized in that: The condensation reaction temperature is room temperature and the time is 1 to 4 hours.
7. The preparation method according to claim 3, characterized in that: The concentration of vitamin E in the vitamin E solution is 50-500 mmol / L; The vitamin E in the vitamin E solution is D-α-vitamin E; The molar ratio of the hydroxyl group in the vitamin E in the vitamin E solution to the carboxyl group in the polyglutamic acid in the mixed solution obtained by the first mixing is (0.5-2):
1.
8. The preparation method according to claim 3, characterized in that: The temperature of the esterification reaction is 25-30° C. and the time is 24-48 hours.
9. The preparation method according to claim 3, characterized in that: After the esterification reaction is completed, the process further includes sequentially performing a first precipitation, a first centrifugation, a first redissolution, a second precipitation, a second centrifugation, a first drying, a second redissolution, dialysis, a third centrifugation and a second drying.
10. Use of the polyglutamic acid-vitamin E amphiphilic conjugate according to claim 1 or 2 or the polyglutamic acid-vitamin E amphiphilic conjugate prepared by the preparation method according to any one of claims 3 to 9 in the field of anti-oxidation or the field of drug-loaded nanomicelles.
Citation Information
Patent Citations
Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
CN101386677A
Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof
CN101663346A
Preparation method of amphipathic gama-polyglutanmic acid nanodrug carrier
CN102698279A
Polyamino acid grafted copolymer and preparation method thereof
CN102875818A
Nanoparticles comprising at least one active agent and at least two polyelectrolytes
CN103370052A
